DALLAS, Oct. 2, 2007 (PRIME NEWSWIRE) -- John Pentony, publisher of StockGuru.com, announced today that the web site has released a new exclusive executive interview with Jonathan Houssian, the Founder and President of RxElite Holdings, Inc., a wholly owned operating subsidiary of Southridge Technology Group, Inc. (OTCBB:SOUT).
During the interview, Mr. Houssian explains that RxElite has contracts in place with every major buyer of any size in the generic drug industry. RxElite participates in niches of the generic drug industry that will not see rapid price erosion due to the complex manufacturing processes with associated high barriers to entry. Mr. Houssian cited his marketing of Sevoflurane and plans to market a Fentanyl transdermal patch as evidence of his growth potential.
Rx Elite understands demand in the generic industry. More significant than demand Mr. Houssian explains is knowing that there is a finite ability to supply a specific generic drug. By focusing on a generic that will experience relatively limited price erosion as the drug transitions into the generic is the key to RxElite's success. Their products and product pipeline include anesthetic gases, transdermal patches and ophthalmic products.
Rx Elite has a six-year history in respiratory and ophthalmic products. Rx Elite participates as a debt free company with retired debt of $16M.
To listen to the StockGuru.com interview Jonathan Houssian, the Founder of RxElite Holdings, Inc., a wholly owned operating subsidiary of Southridge Technology Group, Inc., please visit http://www.stockguru.com/podcasts/?p=13
About RxElite Holdings, Inc.
RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
About StockGuru.com
StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit:
http://www.stockguru.com/stocks.htm
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at (469) 252-3031 or email publisher@stockguru.com. Our services include our Morning, Midday, and After The Bell news releases. Additionally, we profile publicly traded companies on our web site, we do interviews with CEOs or other key executives on our web site, and we have our financial writers cover our companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Disclosure: Pentony Enterprises LLC has been compensated $18,000 directly from the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.